End-stage liver disease (ESLD ) and some other liver-associated comorbidities secondary to hepatitis B virus (HBV) infection are the leading cause of mortality and preferably managed with antiretroviral therapy (ART). However, co-infection of HIV with HBV has complicated the use of ART as the anti-retroviral drugs vary widely in their safety and efficacy and moreover have a dual effect on HIV infection. This article will summarize the clinical data available on the various antiviral agents for deciding the treatment approach and expected the outcome. Tenofovir Tenofovir has activity against both HIV and HBV.
Tenofovir is a nucleotide reverse transcriptase inhibitor with activity against the lamivudine-resistant virus. In clinical trial studies, HIV/HBV coinfected patients treated with tenofovir experienced significant HBV viral load declines compared to placebo. Tenofovir has been…
